Marshall Fordyce, PRESIDENT AND CEO at Vera Therapeutics, Inc. (VERA), sold 35,000 shares at $47.05 ($1.7M) on 2024-11-25, disclosed to the SEC on 2024-11-27.
Scheduled sale ($1.7M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.05 | 6,579 | $310K | 18.5% |
| 2 | $47.05 | 6,579 | $310K | 18.5% |
| 3 | $48.18 | 7,665 | $369K | 22.0% |
| 4 | $48.18 | 7,665 | $369K | 22.0% |
| 5 | $48.76 | 1,875 | $91K | 5.5% |
| 6 | $48.80 | 1,381 |
| $67K |
| 4.0% |
| 7 | $48.80 | 1,381 | $67K | 4.0% |
| 8 | $49.00 | 1,875 | $92K | 5.5% |
| Total | $47.88 avg | 35,000 | $1.7M | 100% |
| Filing → |
| VERA | SELL | 2026-07-09 | $2.0M | — | Filing → |
| VERA | SELL | 2026-06-24 | $702K | — | Filing → |
| VERA | SELL | 2026-05-13 | $680K | — | Filing → |